Crispr Therapeutics Price Target Raised To $100 From $75 At Piper Jaffray
June 07, 2019 at 06:52 AM EDT
Crispr Therapeutics and Vertex expanded their alliance to develop gene editing medicines to treat Duchenne muscular dystrophy and myotonic dystrophy type 1 with Crispr receiving $175M in cash up front.
